Pfizer Inc. (NYSE:PFE) Shares Sold by Livingston Group Asset Management CO operating as Southport Capital Management

Livingston Group Asset Management CO operating as Southport Capital Management lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 64.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,410 shares of the biopharmaceutical company’s stock after selling 38,647 shares during the quarter. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Pfizer were worth $921,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. GoalVest Advisory LLC acquired a new position in shares of Pfizer during the second quarter valued at approximately $39,000. Lake Point Wealth Management acquired a new position in shares of Pfizer during the second quarter valued at approximately $49,000. Harvest Fund Management Co. Ltd raised its holdings in shares of Pfizer by 25,460.0% during the second quarter. Harvest Fund Management Co. Ltd now owns 1,278 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 1,273 shares during the last quarter. Activest Wealth Management acquired a new position in shares of Pfizer during the second quarter valued at approximately $55,000. Finally, KB Financial Partners LLC acquired a new position in shares of Pfizer during the first quarter valued at approximately $62,000. 64.99% of the stock is owned by institutional investors and hedge funds.

PFE has been the subject of several recent research reports. Barclays set a $44.00 price target on Pfizer in a report on Wednesday, November 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $60.00 price target on shares of Pfizer in a report on Friday, November 5th. Benchmark increased their price target on Pfizer from $29.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 5th. Truist increased their price target on Pfizer from $43.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday. Finally, BMO Capital Markets initiated coverage on Pfizer in a report on Thursday, November 18th. They issued an “outperform” rating and a $60.00 price target for the company. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $49.00.

In other news, insider John D. Young sold 150,000 shares of the firm’s stock in a transaction on Thursday, November 11th. The stock was sold at an average price of $50.06, for a total transaction of $7,509,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.05% of the company’s stock.

Pfizer stock traded down $0.19 during mid-day trading on Thursday, hitting $50.89. The company’s stock had a trading volume of 18,556,753 shares, compared to its average volume of 30,943,912. The firm has a market capitalization of $285.64 billion, a PE ratio of 15.15, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72. Pfizer Inc. has a 1 year low of $33.36 and a 1 year high of $52.83. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. The stock’s fifty day moving average is $45.01 and its two-hundred day moving average is $43.27.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.26. Pfizer had a return on equity of 31.66% and a net margin of 27.66%. The company had revenue of $24.09 billion during the quarter, compared to analyst estimates of $22.82 billion. During the same period in the prior year, the business posted $0.72 earnings per share. The firm’s revenue for the quarter was up 134.4% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 4.2 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 6th. Stockholders of record on Friday, November 5th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, November 4th. This represents a $1.56 annualized dividend and a dividend yield of 3.07%. Pfizer’s dividend payout ratio is currently 46.43%.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More: What is a good dividend yield?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.